UPDATE: Morgan Stanley Reiterates On WuXi PharmaTech On Long-Term Investment

By: via Benzinga
In a report published Thursday, Morgan Stanley analyst Bin Li reiterated an Overweight rating on WuXi PharmaTech (NYSE: WX), but removed ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.